Clinical trials
Call for appointment
(352) 294-5000
-
The Stronger Study -
Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE) Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication. This trial will evaluate S-217622 (ensitrelvir), an鈥�
- Investigator
- Nicole M Iovine
- Ages
- 18 Years - N/A
- Sexes
- All
-
Levocarnitine To Protect the Liver From Chemotherapy for Leukemia or Lymphoma This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care鈥�
- Investigator
- Brian Stover
- Ages
- 15 Years - 40 Years
- Sexes
- All
-
A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor This phase III trial compares memantine to placebo in treating patients with primary central nervous system tumors. Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving鈥�
- Investigator
- Brian Stover
- Ages
- 4 Years - 17 Years
- Sexes
- All
-
Using a New Drug Nivolumab in Combination with Chemotherapy to Treat Nasopharyngeal Carcinoma (NPC) This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune鈥�
- Investigator
- Brian Stover
- Ages
- N/A - 21 Years
- Sexes
- All
-
ANBL2131: A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for High-Risk NBL This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with鈥�
- Investigator
- Brian Stover
- Ages
- N/A - 30 Years
- Sexes
- All
-
A Study With DAY101 as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell H This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that is growing, spreading, or getting worse (progressive), has come back (relapsed) after鈥�
- Investigator
- Brian Stover
- Ages
- 180 Days - 22 Years
- Sexes
- All
-
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adol This phase III trial compares hematopoietic (stem) cell transplantation (HCT) using mismatched related donors (haploidentical [haplo]) versus matched unrelated donors (MUD) in treating children, adolescents, and young adults with acute leukemia or鈥�
- Investigators
- Brian Stover, William Slayton
- Ages
- 6 Months - 21 Years
- Sexes
- All
-
A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment o This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after鈥�
- Investigators
- Brian Stover, William Slayton
- Ages
- N/A - 22 Years
- Sexes
- All
-
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Ne Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy using鈥�
- Investigators
- Brian Stover, William Slayton
- Ages
- N/A - 21 Years
- Sexes
- All